期刊文献+

补肾化痰序贯疗法对PCOS伴IR患者内分泌、代谢及血清Apelin表达的影响 被引量:4

Effects of kidney-tonifying and phlegm-eliminating sequential therapy on endocrine,metabolism,and serum apelin level in polycystic ovary syndrome patients with insulin resistance
原文传递
导出
摘要 目的:观察补肾化痰序贯疗法对肾虚痰湿型多囊卵巢综合征(PCOS)伴胰岛素抵抗(IR)患者内分泌、代谢及血清Apelin表达的影响,研究其治疗PCOS伴IR的疗效机制。方法:选取PCOS伴IR患者60例,随机分为两组各30例,治疗组采用中药联合复方醋酸环丙孕酮治疗,对照组单纯采用复方醋酸环丙孕酮治疗,治疗3个周期后观察两组患者肾虚痰湿证候的改善情况,血清促卵泡生成素(FSH)、黄体生成素(LH)、睾酮(T)、雌二醇(E2)的变化,总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)指标的变化,空腹胰岛素(INS)、空腹血糖(FBG)、胰岛素敏感指数(ISI)、体质量指数(BMI)、腰围/臀围(WHR)、Apelin的变化,并对Apelin水平与BMI、WHR、FBG、INS、ISI、HDL的水平进行相关性分析。后对两组患者促排卵治疗3个周期,统计排卵率及妊娠率。结果:(1)治疗组肾虚痰湿证候改善显著优于对照组。(2)两组血清Apelin水平、LH、T、INS均降低,ISI升高,FBG、BMI、WHR改善不明显。(3)治疗组血清Apelin水平、LH、T、INS、ISI水平与对照组比较差异有统计学意义,FBG、BMI、WHR两组比较差异无统计学意义。(4)Apelin水平与BMI、WHR、FBG、INS、ISI呈正相关,与HDL呈负相关。(5)两组排卵率差异不明显,但两组妊娠率差异有统计学意义。结论:(1)补肾化痰序贯疗法能有效改善肾虚痰湿PCOS伴IR患者的全身症状。(2)PCOS患者血清Apelin水平升高,可能参与胰岛素代谢及血管舒缩,而补肾化痰序贯疗法通过降低血清Apelin水平、LH、T、INS的表达,升高ISI,有效改善了肾虚痰湿型PCOS患者的胰岛素抵抗状态,提高了排卵率,从而提高临床妊娠率。 Objective : To observe the effects of kidney - tonifying and phlegm - eliminating sequential therapy on the endocrine, metabolism, and serum apelin level in kidney - deficiency and phlegm - dampness type polycystic ovary syndrome(PCOS) patients with insulin resistance(IR). Methods: Sixty PCOS patients with IR were randomly divided into treatment group ( n = 30) and control group ( n = 30). The treatment group received traditional Chi- nese medicines combined with compound cyproterone acetate, while the control group received compound cyprot- erone acetate alone. After 3 weeks of treatment, the improvements in kidney - deficiency and phlegm - dampness syndrome and the changes in serum follicle - stimulating hormone ( FSH ), luteinizing hormone ( LH ), testosterone ( T), estradiol, total cholesterol, triglyceride, high - density lipoprotein ( HDL), low - density lipoprotein, fasting in-sulin ( FINS), and fasting blood glucose ( FBG), insulin sensitivity index ( ISI ), body mass index ( BMI ), waist - to - hip ratio(WHR) , and serum apelin level were assessed, and the correlations of apelin level with BMI, WHR, FBG, FINS, ISI, and HDL were analyzed. Then, the two groups were treated for 3 courses to promote ovulation. The ovula- tion rate and pregnancy rate were calculated. Results : ( 1 ) The treatment group had a significantly more improvement in kidney -deficiency and phlegm -dampness syndrome than the control group. (2)Both groups showed decreases in apelin, LH,T, and FINS levels and an increase in 1SI;no significant improvements in FBG, BMI, and WHR were found. (3)Serum apelin, LH, T, and FINS levels and ISI showed significant differences between the treatment group and control group, while no significant differences were observed in FBG, BM1, and WHR. (4)Apelin level was positively correlated with BMI, WHR, FBG, FINS, and ISI, but negatively correlated with HDL. (5) Ovulation rate showed no significant difference between the two groups, but there was a significant difference in pregnancy rate between the two groups. Conclusion : ( 1 ) Kidney - tonifying and phlegm - eliminating sequential therapy can effectively relieve the systemic symptoms in kidney -deficiency and phlegm -dampness type PCOS patients with IR. (2)Serum apelin level increases in PCOS patients ,which may be involved in insulin metabolism and vasomotion. Kidney - tonifying and phlegm - eliminating sequential therapy can reduce serum apelin, LH, T, and FINS levels and increase ISI to effectively reduce the insulin resistance in patients with kidney - deficiency and phlegm - dampness type P- COS ,thus increasing their ovulation rate and pregnancy rate.
出处 《湖南中医杂志》 2014年第10期1-5,103,共6页 Hunan Journal of Traditional Chinese Medicine
基金 国家自然科学基金资助项目(编号:81273790)
关键词 补肾化痰中药 多囊卵巢综合征 胰岛素抵抗 APELIN kidneytonifying and phlegm- eliminating traditional Chinese medieines polyeystie ovary syn-drome insulin resistance apelin
  • 相关文献

参考文献9

  • 1DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resist- ance in the polycystic ovary syndrome using the homeostasis model assessment[ J]. Fertil Steri1,2005,83 ( 5 ) : 1454 - 1460.
  • 2Salehi M, Vera RB, Sjeolj A, et al. Pathogenesis of Polyeystie ovary syndrome:what is the role of obesity [ J ]. Metabolism, 2004,53 (3) :358 -376.
  • 3TatemotoK, HosovaM, HabataY, et al. I solation and characterization of a novel endogenous peptide ligand for the human APJ reee - ptor [ J ] . Bioehem Biophys Res Conmaun, 1998,251 (2) :471 - 476.
  • 4Carmina E. Diguosis of polycystic ovary syndrome:from NIH criteria to ESHRE -ASRM guidelines[J]. Minerva Ginecol,2004,56(l) :1 -6.
  • 5李光伟.2型糖尿病系列讲座 第三讲:胰岛素敏感性评估及其在临床研究中的应用[J].中华内分泌代谢杂志,2000,16(3):198-200. 被引量:195
  • 6冯琴,胡义扬.胰岛素抵抗的中医病机证候特点[J].中西医结合学报,2005,3(1):63-65. 被引量:23
  • 7Fedorcsak P, Storeng R, Dale PO, et al. Leptin and leptin binding activity in the preovulatory follicle of polycystic ovary syndrome patients [ J ]. Seand J Clin Lab Invest,2000,60 ( 8 ) :649 - 655.
  • 8Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up - regulated by insulin and obesity [ J ]. Endocrinolo- gy,2005,146(4) :1764 - 1771.
  • 9罗爽,王继东,姚珍薇.多囊卵巢综合征患者血清apelin蛋白水平及意义[J].中国老年学杂志,2012,32(7):1336-1338. 被引量:2

二级参考文献37

  • 1吴启锋,熊尚全,温茂详,杨永东,兰东辉.高血压病中医证型与盐敏感性及胰岛素抵抗关系临床研究[J].福建中医药,2002,33(3):3-4. 被引量:38
  • 2吴向明,周守藩.胰岛素抵抗与心血管病[J].心血管病学进展,1994,15(4):215-217. 被引量:20
  • 3熊曼琪,林安钟,朱章志,蔡文就,郑高飞,钟春宁,陈芝喜,贾可亮,沈穗婷,何敏.加味桃核承气汤对Ⅱ型糖尿病大鼠胰岛素抵抗的影响[J].中国中西医结合杂志,1997,17(3):165-168. 被引量:127
  • 4Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease[J]. N Engl J Med, 1996, 334(15):952-957.
  • 5Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia,and coronary heart disease[J]. Am Heart J, 1991, 121(4 Pt 2): 1283-1288.
  • 6DeFronzo RA. Insulin resistance, hyperinsulinemia, and coronary heart disease: a complex metabolic web [J].J Cardiovasc Pharmacol, 1992, 20 (Suppl 11): S1-S16.
  • 7Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome[J].Fertility and Sterility,2004,(01):19-25.
  • 8Andrea JC,Gerald FW,Valerie B. Cardiometabolic risk in polycystic ova-ry syndrome:a comparison of different approaches to defining the metabolic syndrome[J].Human Reproduction,2008,(10):2352-2358.
  • 9Suheyla G,Cavit C,Ziynet A. Serum fibroblast growth factor 21 levels in polycystic ovary syndrome[J].Gynecological Endocrinology,20 1,(11):819-826.
  • 10Boucher J,Masri B,Daviaud D. Apelin,a newly identified adipokine up-regulated by insulin and obesity[J].Endocrinology,2005,(04):1764-1771.doi:10.1210/en.2004-1427.

共引文献217

同被引文献67

引证文献4

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部